The stock has rallied over 10% in past two trading sessions after reporting turnaround results for March quarter.
Ranbaxy Laboratories is trading lower by 2% at Rs 475, while Sun Pharma down 1% at Rs 634 on the NSE.
The Q4 consolidated net profit jumped 89% yoy at Rs 962 crore, backed by strong growth in voice and data revenues.
Markets are likely to rebound from their recent lows amid firm global cues
Though cement realisation got a boost in the March quarter, lower realisations in the power segment and increasing costs dented operating performance
The company had overall sales volume of 5.63 lakh for the March quarter
Interview with Executive Director & Head of Equities, JPMorgan Asset Management
Management confident of maintaining volume growth and margins in FY15 despite tough environment; plans realistic, say observers
The month is traditionally lean worldwide, so much so that fund managers prefer to go on vacation than trade. But the air of expectancy around the election outcome has kept things heated
Heavy compliance cost may render equity purchases in mother country not worth their while
Nifty, Bank Nifty, Hind Unilever, Tata Steel & Jain Irrigation
FTIL rejects special audit report, plans legal recourse to challenge findings
HDFC Bank, Tata Steel and Tata Motors among top losers for the day
The stock has tanked 9% to Rs 249 after reporting 47% yoy drop in consolidated net profit at Rs 403 crore for Q4FY14.
Sensex slipped 170 points at 22,461 and the Nifty gave off 44 points to end the day at 6,718
HDFC Bank, HUL, Tata Steel were the major draggers in noon deals